Bristol-Myers Squibb: Alzheimer Disease trials

The registry lists 23 Alzheimer Disease studies with Bristol-Myers Squibb as lead sponsor. 9 are open to participants now and 0 have results posted.

Phase 1 12Phase 2 4Phase 3 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose AdministrationRecruitingNCT07780383Phase 1
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseRecruitingNCT07011745Phase 3
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RecruitingNCT07011732Phase 3
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRecruitingNCT06976216Phase 3
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)RecruitingNCT06976203Phase 3
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)RecruitingNCT06947941Phase 3
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)RecruitingNCT06937229Phase 3
• Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseaseRecruitingNCT06808984Phase 2
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)RecruitingNCT06585787Phase 3
• Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseaseActive, not recruitingNCT06268886Phase 2
• Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's DiseaseCompletedNCT01492374Phase 1
• Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163CompletedNCT01454115Phase 1
• Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163CompletedNCT01079819Phase 1
• Multiple Dose Japanese Bridging StudyCompletedNCT01057030Phase 1
• Drug-Drug Interaction Study With Aricept® (Donepezil)CompletedNCT01042314Phase 1
• Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)CompletedNCT01039194Phase 1
• Drug-Drug Interaction Study With RifampinCompletedNCT01002079Phase 1
• Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy SubjectsCompletedNCT00979316Phase 1
• Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's DiseaseCompletedNCT00901498Phase 1
• A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's DiseaseTerminatedNCT00890890Phase 2
• Drug-Drug Interaction (DDI) w/Ketoconazole or FluconazoleCompletedNCT00860275Phase 1
• A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00810147Phase 2
• Drug Interaction Study With a Potential Alzheimer's Disease CompoundCompletedNCT00726726Phase 1